 |
|
Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease
Inès Dufour, Arnaud Devresse, Anais Scohy, Caroline Briquet, Hélène Georgery, Philippe Delaey, Julien De Greef, Eric Goffin, Laura Labriola
Kidney Res Clin Pract. 2023;42(2):275-278. Published online 2023 Mar 31 DOI: https://doi.org/10.23876/j.krcp.22.194
|
|
Citations to this article as recorded by
 Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study
Rani Sawtell, Tianqi Ouyang, Daiana Moreno, Ian Strohbehn, Sherley M. Mejia, Meghan E. Sise
Renal Failure.2025;[Epub] CrossRef Favipiravir Analogues as Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase, Combined Quantum Chemical Modeling, Quantitative Structure–Property Relationship, and Molecular Docking Study
Magdalena Latosińska, Jolanta Natalia Latosińska
Molecules.2024; 29(2): 441. CrossRef Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease
Chia-Chen Chen, Chi-Ya Huang, Jheng-Yan Wu, Mei-Yuan Liu, Min-Hsiang Chuang, Ting-Hui Liu, Ya-Wen Tsai, Wan-Hsuan Hsu, Po-Yu Huang, Ming-Hui Chen, Su-Yen Liu, Mei-Chuan Lee, Kuo-Chuan Hung, Chih-Cheng Lai, I-Ning Yang
Expert Review of Anti-infective Therapy.2024; 22(8): 705. CrossRef Immunosuppressants/tozinameran
Reactions Weekly.2024; 2001(1): 174. CrossRef Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19
Tat Ming Ng, Ziteng Wang, Eric Chun Yong Chan
British Journal of Clinical Pharmacology.2024;[Epub] CrossRef Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study
Wing Ming Chu, Eric Yuk Fai Wan, Zoey Cho Ting Wong, Anthony Raymond Tam, Ian Chi Kei Wong, Esther Wai Yin Chan, Ivan Fan Ngai Hung
eClinicalMedicine.2024; 72: 102620. CrossRef Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment
Kelly E. Duncan, Russ P. Carstens, Kristin L. Butterfield, Yoon Jin, Laura R. Inbody, Andrea K. Schaeffer, Catherine Z. Matthews, Tian Zhao, Shruti Patel, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch
Clinical and Translational Science.2024;[Epub] CrossRef Medication safety in chronic kidney disease
Sonal Singh
Current Opinion in Nephrology & Hypertension.2023; 32(5): 434. CrossRef Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, Michail Papadakis, Ioulia Markaki, Nikolaos Spernovasilis
Infectious Disease Reports.2023; 15(6): 662. CrossRef
|